Phase 1 Obesity Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are considered to be in good general health based on their medical history, blood tests, vital signs, heart tracing (ECG), and physical examination during the screening period
• People between the ages of 18 and 45 (inclusive), of any gender
• People who weigh at least 50 kg and have a Body Mass Index (BMI) between 24.0 and 35.0 (a measure of body weight relative to height, inclusive of those values)

Who may not be able to join:

• People with a personal or family history of a type of thyroid cancer called medullary thyroid cancer, abnormal thyroid cell growth (C-cell hyperplasia), or a hormonal condition called Multiple Endocrine Neoplasia type 2 (MEN2), or whose calcitonin (a hormone measured in blood) is at or above a certain level at screening
• People with a history of long-term (chronic) inflammation of the pancreas, or who have had an acute pancreas attack within the 3 months before screening
• People who have had an acute gallbladder attack within the 3 months before screening
• People who have had a severe low blood sugar episode, or repeated low blood sugar episodes, within the 3 months before screening
• People who have difficulty swallowing, or conditions affecting how the stomach empties or absorbs nutrients — such as previous weight-loss surgery, stomach removal surgery, irritable bowel syndrome, or persistent indigestion (confirm with trial site)
• People with pre-existing conditions that increase the risk of bleeding, such as stomach ulcers with active bleeding, or certain types of bleeding in or around the brain
• People who have had previous surgery that may affect how the body processes medications, or who plan to have surgery during the study period
• People whose physical examination, heart tracing (ECG), blood tests, or vital signs show any results considered medically significant during the screening period
• People who have taken, or plan to take, any medication known to affect certain liver enzymes or drug-processing proteins within 28 days before starting the trial medication
• People with a significant history of heart or stroke-related disease within the 6 months before screening, or at the time of admission to the trial
• People whose heart tracing (ECG) shows results considered clinically significant by the investigating doctor at screening

Important: Always verify eligibility with the trial site directly before applying.